

Index

- 5-HT (5-hydroxytryptamine)
 see serotonin
- 5-HT receptors 32
 classification 252
 distribution 253, 254,
 255, 256–7
 operational
 characteristics
 252–6
 subtypes involved in
 sleep–wake
 regulation 252
- 5-HT_{1A} receptor
 effects of selective
 serotonin reuptake
 inhibitors 259–60
 full agonists at
 autoreceptors and
 partial agonists at
 postsynaptic
 receptors 259
 full agonists at pre- and
 postsynaptic
 receptors 257–9
 operational
 characteristics
 252–3
 role in sleep–wake
 modulation
 257–60
- 5-HT_{1B} receptor
 full agonists at
 postsynaptic
 receptors 260
 operational
 characteristics
 253–4
 role in sleep–wake
 modulation 260
- 5-HT_{2A} receptor, operational
 characteristics 254,
 255
- 5-HT_{2A/2B/2C} receptors
 distribution 261
 effects of 5-HT₂ receptor
 agonists 261
 effects of 5-HT₂ receptor
 antagonists 261–2,
 263
 role in sleep–wake
 regulation 261–3
- 5-HT_{2C} receptor, operational
 characteristics 254,
 255
- 5-HT₃ receptor
 effects of receptor
 agonists and
 antagonists 263–4
 operational
 characteristics 256
 role in sleep–wake
 regulation 263–4
- 5-HT₇ receptor
 effects of receptor
 antagonists 264–5
 operational
 characteristics 256,
 257
- 5-hydroxytryptamine *see* 5-HT
 receptors; serotonin
- acetylcholine
 and REM sleep
 regulation 66
 degradation following
 release 26
 discovery of
 neurotransmitter
 activity 26, 109,
 110
 distribution of
 cholinergic neurons
 25, 26–7
 effects of blocking
 degradation 109–11
 effects on target organs
 27
 extent of
 neurotransmitter
 activity 109, 110
 formation 26
 muscarinic receptors
 27–8

- nicotinic receptors 27–8
 receptor subtypes 27–8
 release across behavioral states 27
 release in the pontine reticular formation during REM sleep 110, 113, 119–21, 122
 role in wakefulness and REM (paradoxical) sleep 26, 27–8, 90–1
see also cholinergic neurons
- acetylcholine release, modulation by muscarinic cholinergic autoreceptors 110, 113, 121–9
- acetylcholine research, clinical relevance 133–4
- acetylcholine transporter blockade, effects on REM sleep 110, 130, 131
- acetylcholinesterase (AChE) 26
- acetylcholinesterase inhibitors, effects on REM sleep 112–16
- active and rest phases, mechanism for alternation between 59–60
- active sleep *see* REM sleep
- adenosine neurotransmitter activity 44–5
 physiology 338
 range of functions 338
 role in energy metabolism 44–5
 role in PGD sleep signal transduction 372–4
 role in the sleep–wake cycle 44–5
- adenosine agonists and antagonists, effects of 339–40
- adenosine and sleep deprivation cause of rise in adenosine 346–7
 effects of energy imbalance 346–7
 effects of NO 346–7
 source of increased adenosine 345–6
- adenosine and vigilance 339–41
 effects of adenosine agonists and antagonists 339–40
 effects of adenosine receptor agonists and antagonists 339–41
 effects of caffeine 340–41
 effects of nucleoside transporter inhibitors 340
- adenosine antagonists, pharmacology 442–7
- adenosine applications in sleep disorders 352–3
- adenosine kinase inhibitors 352
 effects of caffeine 352
 nucleoside transporter blockade 352–3
 potential side-effects 352
- adenosine as a homeostatic sleep factor 339–40
in vivo measurements 341–2
 possible applications in sleep disorders 352–3
- adenosine formation and brain energy metabolism 342–3
 extracellular adenosine 343–5
 intracellular adenosine 342–3
- adenosine hypnogenic action case for A₁R-mediated action in the BF 347–9
 case for A_{2A}R-mediated action in the VLPO 349, 350–2
 neural mechanisms 347–9, 350–2
- adenosine kinase inhibitors 343–4, 345, 352
- adenosine metabolism 343–4
 control of extracellular adenosine levels 343–5
- adenosine receptor agonists and antagonists, effects of 339–41
- adenosine receptors A₁ (A₁R) 338–9
 A_{2A} (A_{2A}R) 338–9
 A_{2B} (A_{2B}R) 338–9
 A₃ (A₃R) 338–9
 case for A₁R-mediated action in the BF 347–9
 case for A_{2A}R-mediated action in the VLPO 349, 350–2

464 Index

- adenosine receptors (*cont.*)
 classification 338–9
 targets for stimulants
 45
- adenosine sleep factor
 16–17
- adenosine triphosphate (ATP)
 and neuronal
 metabolism 44–5
 role in energy
 metabolism 44–5
- adrenaline (epinephrine)
 discovery of 32–3
 synthesis 179–80
see also catecholamines
- African sleeping sickness
 366
- age, variation in REM sleep
 61
- age-related circadian
 changes, melatonin
 treatment 294
- ageing and sleep 443–5
- ageing population, clinical
 relevance of ACh
 research 133–4
- agomelatine 299–300,
 301
- aminergic neurons, rates of
 firing in sleep–wake
 regulation 250–2
- AMPA glutamate receptors
 225
- amphetamines 440–1
- amphibians, brain electrical
 activity in rest state
 60–1
- anesthesia, effects on the
 prefrontal cortex
 125, 126
- anesthetics 433–4
- animal models, and the
 nature of cataplexy
 416–18
- animal studies of
 neurotransmitters
 24
- anticonvulsant effects of
 melatonin 290
- antidepressants and sleep
 435–8
 cAMP regulated
 pathways 435–6
 sleep and depression
 436–8
 sleep–wakefulness
 effects of first
 generation
 compounds 156
- antioxidant properties of
 melatonin and
 its metabolites
 284–5
- antipsychotic medications
 and sleep 438–40
- arousal
 effects of orexin
 deficiency 404,
 419–20
 in orexin- and orexin
 receptor-deficient
 rodents 415
 role of melanin-
 concentrating
 hormone (MCH)
 426
- arousal systems
 effects of sleep-active
 WSNs 13, 14
 efferents from POA
 sleep-active neurons
 8, 9
 GABAergic control 7,
 10, 11, 12
 GABAergic projections
 from POA
 sleep-active neurons
 8, 9
- integration in the
 hypothalamus
 426–7
- atypical antipsychotics
 440
- automatic behaviors 405,
 406
- autoreceptors, definition 110,
 121 *see also*
 muscarinic
 cholinergic
 autoreceptors
- barbiturates 433–4
- basal forebrain (BF)
 case for A₁R-mediated
 action in 347–9
 effects of glutamate
 neurotransmission
 227
- basal forebrain cholinergic
 neurons 26–9
 activity levels 27
 distribution 25, 26–7
 functions 28–9
- basal forebrain GABAergic
 neurons 40–1
- basal forebrain NO-ergic
 mechanisms 326–7
- basal forebrain sleep-active
 neurons 6
- Benzedrine™ 440–1
- benzodiazepine receptors
 433–4
- benzodiazepines 433–5
 areas of the brain
 involved 434–5
 effects on sleep 434,
 435
 GABAergic regulation
 434–5
 tolerance and
 dependence 435
- beta-trace biomarker 368–9

- biochemical investigation of neurotransmitters 23–4
- birds, REM sleep 60–1
- blind people, circadian rhythm problems 294
- body temperature, and sleep propensity 10–14
- Borbély's two-process theory of sleep-wake regulation 337
- brain energy metabolism, and adenosine formation 342–3
- brain imaging techniques (MRI, PET) 24
- brain regions controlling REM sleep 24–6
- brain regions controlling wakefulness 24–6
- brainstem
effects of glutamate neurotransmission 225–6
mechanisms which mediate NO actions 325–6
- brainstem cholinergic neurons 26–9
distribution 25, 26–7
- bupirone 259
- c-Fos immunoreactivity marker 3–4, 374
- caffeine
adenosine antagonist 373–4
adenosine receptor targets 45
effects of 340–1
non-specific adenosine receptor antagonist 340–1
- pharmacology 441–7
sleep effects 352
- cancer, exogenous administration of melatonin 283
- cataplexy
distinctions across species 416–18
findings from animal models 416–18
and LC neuron activity 34
nature of 416–18
possible causes 95
role of histamine neurons 38
role of orexin (hypocretin) neurons 38–9
as symptom of narcolepsy 38–9
symptoms and treatment 33, 403–5, 406
see also narcolepsy-cataplexy
- catecholamine cell groups, classification 183–4, 191
- catecholamines
actions on sleep 33–4
biosynthetic pathway 33, 179–80
depletion by reserpine 33
see also adrenaline; dopamine; noradrenaline
- cerebral cortex, acetylcholine release 27
- chemical lesion techniques 24
- chemical neurotransmission, discovery of 26
- chemical sampling of neurotransmitters 23–4
- choline acetyltransferase (ChAT) 26–7
- choline transporter blockade, effects of REM sleep 110, 129–30
- cholinergic basal forebrain neurons 26–9
activity levels 27
functions 28–9
- cholinergic brainstem neurons 26–9
- cholinergic LDT/PPT neurons
activity levels 27
production of NO 28
- cholinergic medial septum neurons, functions 28–9
- cholinergic neurons
distribution 25, 26–7
rates of firing in sleep-wake regulation 250–2
see also acetylcholine
- cholinergic synapse (brain) 110, 121
- cholinergic synapse mechanisms 109, 110
effects of blocking ACh degradation 109–11
- circadian changes, age-related 294
- circadian clock genes, role in control of dopamine systems 186
- circadian control of histamine synthesis and release 146–7
- circadian pacemaker (suprachiasmatic nucleus) 186

466 Index

- circadian pattern of
 melatonin secretion
 285–6
- circadian phase-shifting
 effects of melatonin
 293–4
- circadian process,
 sleep–wake
 regulation 337
- circadian rhythms
 body temperature and
 sleep 10–13
 disruption by light 194
 problems in blind
 people 294
- circadian sleep disorders,
 benefits of
 exogenous
 administration of
 melatonin 283
- circadian wakefulness signal,
 effects of orexin
 deficiency 420–2
- citalopram 260
- clinical effects of
 dopaminomimetics
 190, 193–4
- clinical potential of
 glutamate receptor
 agonists/antagonists
 239–40
- clinical relevance of ACh
 research 133–4
- CNS stimulants and sleep
 440–50
 adenosine antagonists
 442–7
 caffeine 441–7
 dopamine-acting drugs
 440–1
 modafinil and
 wakefulness 447–8
 nicotine 448–50
 cocaine 440–1
- cold-sensitive neurons (CSNs)
 in the POA
 13–14
- cortex, effects of glutamate
 neurotransmission
 227–8
- cortical activation during
 wakefulness 145
- cortical synchronization,
 effects of cortistatin
 392–4
- cortistatin
 and sleep–wake
 regulation 392–4
 discovery 392
 effects on cortical
 synchronization
 392–4
 effects on slow wave
 sleep 392–4
 receptors 392
 structure 392
 synthesis 392
- cyclopyrrolones 434
- cytokines, as sleep factors
 316
- daytime sleepiness, in
 Parkinson's disease
 202–5
- delayed sleep phase
 syndrome,
 melatonin
 treatment 294
- depression
 and sleep 436–8
 antidepressants and
 sleep 435–8
 depression treatments
 (serotonin-related)
 31
- diseases, effects on REM
 sleep 61
- dopamine
 and REM sleep
 regulation 65
 catabolic pathways 182
 cell loss 179
 cellular and subcellular
 effects 182–3
 influence on wake–sleep
 behaviors 179
 metabolism 182
 neuromodulatory
 physiological effects
 182–3
 neurotransmitter
 activity 44
 range of functions in
 the CNS 179
 reuptake from the
 synapse 180–2
 role in control of
 wakefulness 44
 synthesis 179–80,
 181
 see also catecholamines;
 Parkinson's disease
- dopamine-acting drugs
 440–1
- dopamine circuits in the
 brain
 axon collateralization
 185
 classification 183–4, 191
 functional anatomy
 183–5, 191
 mesocorticolimbic
 pathway 184
 nigrostriatal pathway
 184
 subparafascicular
 thalamus cell group
 185
 tuberohypophyseal
 pathway 184–5
 tuberoinfundibular
 pathway 184–5

- dopamine modulation of
wake-sleep state
190–200
- activation of dopamine
receptor subtypes
193–4
- affinity of stimulants for
DAT 190, 192
- animal studies 200–2
- clinical effects of
dopaminomimetics
190, 193–4
- exogenous
dopaminomimetic
effects 181, 192–4
- functional anatomy of
mesotelencephalic
dopamine neurons
195–200
- genetic modification of
DAT function 190,
192–3
- light disruption of
circadian rhythms
194
- mesotelencephalic
system 190–2
- pharmacological
evidence 181,
192–4
- physiology of
mesotelencephalic
dopamine neurons
188, 194–5
- role of midbrain
dopaminergic
neurons 200–2
- dopamine receptors
activation of subtypes
193–4
- characteristics of
subtypes 182–3
- classification of subtypes
182
- dopamine signaling
behavioral state
influences on 188,
189–90
- circadian influences on
186–9
- diurnal variations in
186–9
- homeostatic influences
on 189
- role of circadian clock
genes 186
- dopamine transporter (DAT)
44, 180–2
- affinity of stimulants
190, 192
- genetic modification of
DAT function 190,
192–3
- dopaminergic D-1 and D-2
receptor antagonists
439–40
- dopaminergic inputs to TMN
histaminergic
neurons 150
- dopaminomimetics
clinical effects 190,
193–4
- effects on REM sleep
200
- effects on wake-sleep
state 181, 192–4
- sleep-related side effects
200
- dorsal raphe nucleus (DRN)
chemoarchitecture
250
- efferents from POA
sleep-active neurons
8
- GABA release during
sleep 7, 10
- dorsal raphe serotonergic
neurons 247
- afferent connections
249, 250
- efferent connections
247–8, 249
- rates of firing in
sleep-wake
regulation 250–2
- EEG (electroencephalogram)
24
- activation by blocking
ACh degradation
109–11
- activity during REM
sleep 109–11
- activity during
wakefulness 145
- in mammalian species
60–1
- EEG excitability,
autoreceptor
modulation of ACh
110, 123–9
- electrical lesion techniques
24
- electrographic recording
techniques (EEG,
EMG, EOG) 24
- electrophysiological
investigations of
neurotransmitters
23–4
- EMG (electromyogram) 24
in mammalian species
60–1
- energy balance
influence on sleep-wake
regulation
424–7
- role of melanin-
concentrating
hormone (MCH)
424
- role of orexin 424

468 Index

- EOG (electrooculogram) 24
in mammalian species 60–1
- epilepsy in children, effects of melatonin 290
- epinephrine *see* adrenaline
- estradiol, effects on melatonin receptors 289–90
- excessive daytime sleepiness 403–5, 406
- excessive nocturnal movement, in Parkinson's disease 202, 203, 205–6
- flip-flop sleep switch model 40, 41–2
interaction of orexin (hypocretin) and MCH 426
proposed role of orexin (hypocretin) neurons 391
role of neuropeptide S (NPS) 395–6, 397
role of POA sleep-active neurons 14
- fluoxetine 260, 437–8
- GABA (γ -amino-butyric acid) and REM sleep regulation 66–8
discovery 40
- GABA high affinity transporter 41
- GABA synthesis 41
POA sleep-active neurons 4, 5
- GABA receptors 41
actions of sedative hypnotic drugs 17
- GABA release during sleep locations 5, 10, 11, 12
possible source 7, 10
- GABA shunt 41
- GABA-A receptor complex 434
- GABA-A receptors and sleep 433–5
location 434
subunits 434
- GABAergic activity, effects of melatonin 295–9, 300
- GABAergic basal forebrain neurons 40–1
- GABAergic brainstem neurons, role in REM sleep 35, 42
- GABAergic control of arousal systems 7, 10, 11, 12
- GABAergic drugs benefits and limitations 224
sleep-related side effects 224
- GABAergic inhibition based model of REM sleep regulation 69–70, 71
- GABAergic inputs to TMN histaminergic neurons 150
- GABAergic neurons distribution 40–1
gating paradoxical sleep onset 88–9
inhibition of monoaminergic neurons in PS 91–4
POA neurons 40–1
roles in sleep-wake control 35, 42–3
- GABAergic POA projections to arousal systems 8, 9
- gaboxadol 435
- galanin inputs to TMN histaminergic neurons 150
- genetic engineering approaches to neurotransmitter study 24
- gepirone 259
- ghrelin role in sleep-wake regulation 318–21, 322, 323
sources in the body 318
structure 318, 319
see also orexin-ghrelin-NPY circuit
- glutamate interplay with GABA 224–5
metabolism 43–4
neurotransmitter activity 43–4, 224–5
role in paradoxical sleep 89–90
- glutamate neurotransmission basal forebrain 227
brainstem 225–6
cortex 227–8
hypothalamus 226–7
in brain areas important for sleep and arousal 225–8
in brain areas which regulate vigilance 225–8
lateral and dorsomedial hypothalamus 226–7

- medial preoptic area of
the hypothalamus
227
- medulla 225–6
- orexin (hypocretin)-
containing neurons
226–7
- pedunclopontine
tegmentum (PPT)
226
- pons 225–6
- pontine reticular
formation 225–6
- suprachiasmatic nucleus
226
- thalamus 227–8
- glutamate receptor
agonists/antagonists
clinical potential
239–40
competitive AMPA
receptor antagonist
235
competitive NMDA
receptor antagonist
234–5
effects on brain arousal
228–40
effects on sleep and EEG
228–40
ionotropic receptor
manipulations
228–35
metabotropic receptor
manipulations
235–9
noncompetitive NMDA
receptor antagonists
228–34
potential use in sleep
disorders 239–40
glutamate receptors 44, 225
AMPA 225
ionotropic 225
- kainate 225
- metabotropic 225
- NMDA 225
- glycine
formation 43
high affinity transporter
system 43
mode of action 43
neurotransmitter
activity 43
role in REM muscle
atonia 43
- glycinergic neurons,
distribution 43
- hallucinations 405, 406
- haloperidol 438
- histamine (HA)
and behavior 156
and REM sleep
regulation 65–6
circadian control of
synthesis and
release 146–7
discovery 36
discovery of
neurotransmitter
activity 36,
145–6
in brain mast cells 37
inactivation by
catabolism 146,
147
levels in the brain
146–7
neuronal pool in the
brain 146, 147
non-neuronal pool in
the brain (mast
cells) 146
receptors 37
role in the sleep–wake
cycle 37–8
synthesis 30, 36–7
- synthesis in the CNS
146–7
turnover in the brain
146, 147
- histamine and
sleep–wakefulness
studies 156–66
- H₁ receptor agonists/
antagonists
162–3
- H₂ receptor agonists/
antagonists 163
- H₃ receptor agonists/
antagonists 163–5
- HA administration
161–2
- biochemical and
molecular studies
158–60
- c-Fos indication of TMN
neuronal activity
159–60
- early work 156–7
- effects of first
generation
antihistamines 156
- electrophysiological
studies 157–8
- HDC (L-histidine
decarboxylase)
knockout mice
160
- inactivation or lesion of
the TMN 165–6
- manipulation of HA
synthesis and
degradation 161
- measurement of HA
release and
turnover 158–9
- pharmacological studies
161–6
- role of the posterior
hypothalamus 157

470 Index

- histamine neurons *see*
 histamine TMN
 (tuberomammillary
 nucleus) neurons
- histamine receptors
 153–6
 H₁ receptor 153–4
 H₂ receptor 154–5
 H₃ receptor 155–6
 H₄ receptor 153
 subtypes classification
 153
- histamine TMN
 (tuberomammillary
 nucleus) neurons
 36–8, 147–8
 activity levels 37–8
 localization in the TMN
 37
 method of release of
 histamine 37
 rates of firing in
 sleep–wake
 regulation 250–2
- homeostatic control of sleep,
 role of the POA
 hypnogenic system
 15
- homeostatic process,
 sleep–wake
 regulation 337,
 338
- homeostatic sleep factors,
 adenosine 339–40,
 341–2, 352–3 *see also*
 sleep factors
- humoral theory of sleep
 regulation
 363
- hypnogenic mechanism, in
 the hypothalamic
 POA 3
- hypnogenic sleep factors
 15–17
- adenosine 16–17
 IL-1 β 16
 PGD2 17
see also sleep factors
- hypnotics 433–5
- hypocretin *see* orexin
 (hypocretin)
- hypothalamic preoptic area
 (POA) *see* preoptic
 area (POA)
- hypothalamus
 discovery of orexins
 (hypocretins)
 388–9
 distinct functions of the
 various nuclei
 388–9
 effects of glutamate
 neurotransmission
 226–7
 integration of arousal
 systems 426–7
 location of GABA-A
 receptors 434
- imidazopyridines 434
- immune function disorders
 283
- immunohistochemical
 investigation of
 neurotransmitters
 23–4
- insomnia
 exogenous
 administration of
 melatonin 283
 genetic influences
 445–6
- interferon alpha 2, as a sleep
 factor 316
- interleukin 1 (IL-1) sleep
 factors 316
- interleukin-1 β (IL-1 β) sleep
 factor 16
- ionotropic glutamate
 receptors 225
 manipulations 228–35
- ipsapirone 259
- jet lag symptoms, melatonin
 treatment 293–4
- kainate glutamate receptors
 225
- lateral and dorsomedial
 hypothalamus,
 effects of glutamate
 neurotransmission
 226–7
- lateral hypothalamus (LH)
 integration of arousal
 systems 426–7
 role in sleep–wake
 regulation
 424–6
- LC *see* locus coeruleus
- LDT/PPT (laterodorsal
 tegmentum/
 pedunculopontine
 tegmentum)
 cholinergic neurons
 25, 26–7
 activity levels 27
 production of NO
 28
- light/dark cycle, influence on
 melatonin secretion
 285–6
- lithium 436
- locus coeruleus (LC)
 GABA release during
 sleep 7, 10
 projections from POA
 sleep-active neurons
 8
 role in REM sleep
 generation 61–3

- locus coeruleus
 noradrenaline
 neurons 32–4
 actions on sleep 33–4
 activity levels 33–4
 distribution 33
- LY 156735 (melatonin agonist) 301
- mammals, REM sleep 60–1
- mastocytosis 366
- MCH (melanin concentrating hormone) neurons, role in paradoxical sleep 96–7
- MCH^{-/-}; orexin^{-/-}* (double knockout) mice 424–6
- medial pontine reticular formation, effects of autoreceptor modulation of ACh 110, 123–5
- medial preoptic area of the hypothalamus, effects of glutamate neurotransmission 227
- medial septum cholinergic neurons
 distribution 25, 26–7
 functions 28–9
- median preoptic nucleus (MnPN)
 efferents to arousal systems 8, 9
 neuronal projections to the PLH 4
 sleep-active neurons 3–4, 5, 6
- median raphe serotonergic neurons 247
 afferent connections 249, 250
- efferent connection 247–8, 249
- medulla, effects of glutamate neurotransmission 225–6
- melanin-concentrating hormone (MCH)
 influence on sleep-wake regulation 424–7
 interaction with orexin 424–6
- MCH^{-/-}; orexin^{-/-}* (double knockout) mice 424–6
- role in arousal 426
- role in energy balance 424
- role in the sleep switch 426
- melatonin
 antioxidant properties 284–5
 biosynthesis 283–4
 chemical nature 283
 circulation and half life 284
 discovery 283
 functions 287
 influence of light/dark cycle 283
 mechanism of action 287–9
 metabolism 284–5
 mood stabilizing and anticonvulsant effects 290
- pineal gland
 biosynthesis and secretion 283
- possible modulation of GABAergic activity 295–9, 300
- receptor binding 287–9
 secretion 283, 284
- therapeutic exogenous administration 283
 use in pediatric epilepsy 290
- melatonin agonists
 agomelatine 299–300, 301
 LY 156735 301
 ramelteon (RozeremTM) 300–1, 435
 use in treatment of sleep disorders 299–301
- melatonin metabolism
 286–7
 antioxidant properties of metabolites 284–5
- melatonin modulation of human sleep 290–1
 circadian phase-shifting effects of melatonin 293–4
 effects of endogenous melatonin administration 291–4
 neuropharmacological mechanisms 295–9, 300
 opening of the sleep gate 290–1
 treatment of age-related circadian changes 294
 treatment of circadian rhythm problems in blind people 294
 treatment of delayed sleep phase syndrome 294
 treatment of jet lag symptoms 293–4

472 Index

- melatonin modulation of
 human sleep (*cont.*)
 treatment of sleep
 disorders 291–4
 wake-maintenance zone
 (“forbidden zone”) 291
- melatonin receptors
 effects of clinically
 administered drugs 289–90
 functions 287–9
 regulation 289–90
- melatonin secretion
 circadian pattern 285–6
 control by the
 suprachiasmatic
 nucleus 285–6
 influence of light/dark
 cycle 285–6
 interindividual
 differences 286
 regulation 285–6
 up-regulation 286
- mesocorticolimbic dopamine
 pathway 184
- mesotelencephalic system
 190–2
 functional anatomy of
 dopamine neurons
 195–200
 physiology of dopamine
 neurons 188, 194–5
- metabotropic glutamate
 receptor 225
 manipulations 235–9
- methylphenidate 440–1
- methylxanthines, adenosine
 receptor targets 45
- mianserine 437
- microdialysis–
 electrochemical
 detection 23–4
- midbrain dopaminergic
 neurons, role in
 regulation of
 wake–sleep state
 200–2
- mioflazine 340
- mirtazapine 437–8
- modafinil and wakefulness
 447–8
- molecular biological study of
 neurotransmitters
 24
- monoamine oxidase
 inhibitors (MAOIs)
 31, 33, 435–6
- monoaminergic systems,
 activity during
 wakefulness
 145
- monoaminergic theory of
 sleep and waking
 31–2
- mood stabilizers 436
 effects of melatonin
 290
- muramyl peptides (Factor S)
 315–16
- muscarinic acetylcholine
 receptors 27–8
- muscarinic cholinergic
 autoreceptors,
 modulation of ACh
 release 110, 113,
 121–9
- muscarinic cholinergic
 receptors
 autoreceptor subtype
 123, 124
 role in REM sleep
 generation 115,
 116–18
 subtypes 116–18
- muscle atonia in REM, role
 of glycine 43
- mutual inhibitory model of
 REM sleep
 regulation 69
- narcolepsy
 and LC neuron activity
 34
 link with orexins
 (hypocretins) 389
 pharmacology of
 orexins
 (hypocretins) 450–1
 possible causes 95
 role of orexin
 (hypocretin)
 neurons 38–9
 side effects of
 dopaminomimetics
 200
 symptoms 38–9
 treatments 33
- narcolepsy–cataplexy, in
 orexin- and orexin
 receptor-deficient
 rodents 415
- narcolepsy–cataplexy in
 humans 403–9
 and loss of orexin
 signaling 407–9
 automatic behaviors
 405, 406
 cataplexy symptoms and
 treatment 403–5,
 406
 clinical diagnosis 405–7
 disruption of sleep–wake
 regulation 405–7
 excessive daytime
 sleepiness 403–5,
 406
 fragmented nocturnal
 sleep 405, 406,
 409
 hallucinations 405, 406

- signs and symptoms 403, 406
- sleep paralysis 405, 406
- narcolepsy-like phenotype in Parkinson's disease 202–5
- network model of PS onset and maintenance 97–8
- neurochemical regulatory mechanisms, POA sleep-active neurons 15–17
- neurodegenerative diseases, benefits of exogenous administration of melatonin 283
- neuromodulator sleep factors 317–18
- neuronal metabolism, and ATP 44–5
- neurons
 - electrical properties 24
 - generation of electrical signals 23
- neuropeptide S (NPS) and sleep-wake regulation 395–6, 397
- and the sleep switch (flip-flop) model 395–6, 397
- anxiolytic properties 395, 396
- promotion of wakefulness 395–6, 397
- neuropeptide S (NPS) receptor 395
- neuropeptide Y (NPY) role in sleep-wake regulation 319, 321–2, 323
- source in the brain 321
- structure 319, 321
- see also* orexin-ghrelin-NPY circuit
- neuropeptides and sleep-wake regulation
 - cortistatin 392–4
 - hypocretins (orexins) 388–91
 - neuropeptide S (NPS) 395–6, 397
 - study methods 388–9, 392, 396
 - suitability as sleep circuit modulators 396–7
 - urotensin II 394–5
 - use of reverse genetics to study 388–9, 392, 396
- neurotransmitter metabolism 24
- neurotransmitter sleep factors 317–18
- neurotransmitter systems
 - investigative methodologies 23–4
 - involvement in sleep-wake stages 433
- neurotransmitters
 - animal studies 24
 - cortical activation during wakefulness 145
 - discovery 24
 - discovery of chemical neurotransmission 26
 - functions 23
- reciprocal interaction
 - model of REM sleep 34–6
- neurotransmitters for REM sleep regulation 63–70
 - acetylcholine 66
 - dopamine 65
 - GABA 66–8
 - GABAergic inhibition based model 69–70, 71
 - histamine 65–6
 - interactions between 68–70
 - mutual inhibitory model 69
 - noradrenaline 63–4
 - orexin (hypocretin) 68
 - reciprocal interaction model 68–9
 - serotonin 65
- nicotine, effects on sleep 131–2, 448–50
- nicotinic acetylcholine receptors 27–8
- nicotinic cholinergic receptors
 - role in arousal state control 131–2
 - structure 131
 - subtypes 131
- nigrostriatal dopamine pathway 184
- nitric oxide (NO), production by LDT/PPT cholinergic neurons 28
- nitric oxide (NO) as a sleep factor
 - actions in the suprachiasmatic nucleus 327–8

474 Index

- nitric oxide (NO) (*cont.*)
- basal forebrain NO-ergic mechanisms 326–7
 - brainstem mechanisms which mediate NO actions 325–6
 - diurnal rhythm of NOS activity 327
 - dynamics of NO release 327
 - effects in sleep deprivation 346–7
 - effects of NOS inhibitors 324
 - formation by nitric oxide synthase (NOS) 322–3
 - isoforms of nitric oxide synthase (NOS) 322–3
 - neurotransmitter functions 322
 - NO donor studies 324–5
 - role in sleep–wake regulation 322–8
 - studies of NOS-deficient transgenic mice 326
 - nitric oxide synthase (NOS) 322–3
 - NMDA glutamate receptors 225
 - nocturnal sleep, fragmented 405, 406, 409
 - non-mammalian species, brain electrical activity in rest state 60–1
 - non-REM (NREM) sleep (slow wave sleep) 60
 - effects of autoreceptor modulation of ACh 125, 126
 - effects of orexin 322, 323, 388–91, 424–7
 - deficiency 422
 - and the gating of REM sleep 418–19
 - discovery 38, 388–9
 - integration into the reciprocal interaction model 389–91
 - interaction with MCH 424–6
 - link with narcolepsy 389
 - pharmacology 450–1
 - role in energy homeostasis 424
 - structure and formation 38
 - wake-promoting effects 389–1
 - orexin- and orexin receptor-deficient rodents
 - effects on arousal 415
 - effects on REM sleep 415–16
 - MCH^{-/-}; orexin^{-/-}* (double knockout) mice 424–6
 - nature of cataplexy 416–18
 - orexin/ataxin-3* transgenic mice and rats 413–14, 416–18
 - orexin^{-/-}* mouse phenotype 409, 410–13
 - orexin receptor null mice 414–15, 418–19, 424
 - phenotypic characterization 409–11, 416
 - noradrenaline (NA) (norepinephrine)
 - and REM sleep regulation 63–4
 - biosynthetic pathways 33
 - discovery of 32–3
 - discovery of neurotransmitter activity 32–3
 - enhancement of extracellular concentration 33
 - increase during REM sleep deprivation 71–3
 - receptors 34
 - synthesis 179–80
 - noradrenaline LC neurons 32–4
 - actions on sleep 33–4
 - activity levels 33–4
 - noradrenaline neurons
 - distribution 33
 - rates of firing in sleep–wake regulation 250–2
 - noradrenaline reuptake transporter (NERT) 33
 - nucleoside transporter inhibitors 340, 352–3
 - obestatin 321
 - olanzapine 438, 439
 - orexin (hypocretin)
 - and REM sleep regulation 68
 - and sleep–wake regulation 318,

- requirements for
narcolepsy-
cataplexy
415
- requirements for REM
sleep dysregulation
415
- orexin-ataxin-3* transgenic
mice and rats
413–14, 416–18
- orexin deficiency and
abnormal sleepiness
404, 419–24
- abnormal regulation of
non-REM sleep
422
- arousal deficit 404,
419–20
- consequences of orexin
signaling deficiency
424
- effects on the circadian
wakefulness signal
420–2
- fragmentation of
vigilance states
422–4
- orexin-ghrelin-NPY circuit
318–22, 323
- orexin*^{-/-} mouse phenotype
- orexin (hypocretin) neurons
activity during states of
vigilance 391
- activity levels 39, 40
- distribution 38
- effects of glutamate
neurotransmission
226–7
- in the perifornical
hypothalamus 38–9
- proposed role in the
sleep-switch
(flip-flop) model
391
- rates of firing in
sleep-wake
regulation 250–2
- receptors 38
- role in cataplexy 38–9
- role in narcolepsy 38–9
- role in paradoxical sleep
95–6, 97
- role in the sleep-wake
cycle 39, 40
- orexin (hypocretin)
neuropeptide
system 402–3, 404
- actions 403
- discovery of orexins
(hypocretins) 402,
403, 404
- narcolepsy-cataplexy in
humans 403–9
- prepro-orexin*
(*prepro-hypocretin*)
gene 402, 403, 404
- projection of orexin
neurons 403, 404
- receptors 403
- structure 402, 403, 404
- orexin (hypocretin) receptor
null mice 414–15,
418–19, 424
- orexin (hypocretin) receptors
403
- orexinergic inputs to TMN
histaminergic
neurons 150
- oxidative damage, benefits of
exogenous
administration of
melatonin 283
- pain relief, clinical relevance
of ACh research
133–4
- paradoxical sleep (PS),
discovery and early
studies 85–6 *see also*
REM sleep
- paradoxical sleep (PS) onset
and maintenance
GABAergic inhibition of
monoaminergic
neurons 91–4
- GABAergic neurons
gating onset 88–9
- network model 97–8
- pontine structures
affecting 85–6
- reciprocal interaction
model 86–8
- role of acetylcholine
90–1
- role of glutamate
89–90
- role of MCH peptidergic
neurons 96–7
- role of orexin
(hypocretin)
neurons 95–6, 97
- role of the posterior
hypothalamus (PH)
95, 96–7
- role of the
sublaterodorsal
nucleus (SLD)
88–91
- structures involved
94–7
- Parkinson's disease (PD)
daytime sleepiness
202–5
- effects of dopamine cell
loss 179
- excessive nocturnal
movement 202,
203, 205–6
- narcolepsy-like
phenotype 202–5
- periodic leg movements
202, 203, 205–6

476 Index

- Parkinson's disease (*cont.*)
- REM sleep behaviour
 - disorder 202, 203, 205–6
 - side-effects of treatment 200
 - sleep disorders 440
 - sleep-onset REM periods (SOREMs) 202–5
 - sleep-related effects of dopaminomimetics 200
 - state-related dysfunction 202–6
 - substrates underlying excessive nocturnal movement 205–6
 - substrates underlying impaired arousal 203–5
 - thalamocortical arousal state dysfunction 202–5
 - see also* dopamine
 - PCPA (*p*-chloro-phenylalanine), effects of 31–2
 - perifornical hypothalamus, orexin (hypocretin) neurons 38–9, 95–6, 97
 - perifornical lateral hypothalamus (PLH)
 - efferents from POA
 - sleep-active neurons 8, 9
 - GABAergic control of orexin (hypocretin) neurons 7, 10, 11, 12
 - neuronal projections from the MnPN 4
 - periodic leg movements of sleep 179, 185
 - in Parkinson's disease 202, 203, 205–6
 - peripheral vasculature, effect of urotensin II 394–5
 - PG *see* prostaglandin
 - PGO (pons, lateral geniculate nucleus, occipital cortex) waves 27
 - PGO spikes
 - and PCPA 32
 - and serotonin 32
 - pharmacological investigation of neurotransmitters 23–4
 - pharmacology
 - adenosine antagonists 442–7
 - aging and sleep 443–5
 - amphetamines 440–1
 - anesthetics 433–4
 - antidepressants and sleep 435–8
 - antipsychotic medications and sleep 438–40
 - atypical antipsychotics 440
 - barbiturates 433–4
 - Benzedrine™ 440–1
 - benzodiazepines 433–5
 - cAMP regulated pathways 435–6
 - CNS stimulants and sleep 440–50
 - cocaine 440–1
 - cyclopyrrolones 434
 - dopamine-acting drugs 440–1
 - dopaminergic D-1 and D-2 receptor antagonists 439–40
 - fluoxetine 437–8
 - GABA-A receptors and sleep 433–5
 - gaboxadol 435
 - genetic influences in insomnia 445–6
 - haloperidol 438
 - hypnotics 433–5
 - imidazopyridines 434
 - lithium 436
 - methylphenidate 440–1
 - mianserine 437
 - mirtazapine 437–8
 - modafinil and wakefulness 447–8
 - monoamine oxidase inhibitors (MAOIs) 435–6
 - mood stabilizers 436
 - nicotine and sleep 448–50
 - olanzapine 438, 439
 - orexins (hypocretins) and sleep 450–1
 - ramelteon 435
 - reboxetine 437–8
 - risperidone 438
 - serotonin reuptake inhibitors 435–6
 - trazodone 437
 - tricyclic antidepressants (TCAs) 435–6
 - venlafaxine 437–8
 - zolpidem 434, 437–8
 - zopiclone 434
 - pineal gland, biosynthesis and secretion of melatonin 283
 - plasticity related genes, activation 33
 - PLH *see* perifornical lateral hypothalamus
 - POA *see* preoptic area

- pons, effects of glutamate neurotransmission 225–6
- pontine cholinergic agonists, effects on REM sleep 112–16
- pontine region
distinct nuclear groups 62–3
role in REM sleep generation 61–3
- pontine reticular formation
ACh release during REM sleep 110, 113, 119–21, 122
effects of glutamate neurotransmission 225–6
- pontis reticularis oralis (PRO), role in REM sleep generation 61–3
- posterior hypothalamus (PH)
GABA release during sleep 7, 10, 11, 12
role in control of sleep–wake cycle 157
role in PS onset and maintenance 95, 96–7
- PPT (pedunculopontine tegmentum), effects of glutamate neurotransmission 226
- prefrontal cortex
effects of anesthesia 125, 126
effects of autoreceptor modulation of ACh 125–9
- effects of sleep deprivation 125, 126
- preoptic area (POA)
GABAergic neurons 40–1
- preoptic area (POA)
hypnogenic system
hypnogenic mechanism 3
role in homeostatic control of sleep 15
thermosensitive component 10–14
- preoptic area (POA)
sleep-active neurons 3
actions of sedative hypnotic drugs 17
c-Fos immunoreactivity mapping 3–4
effects of adenosine sleep factor 16–17
effects of IL-1 β sleep factor 16
effects of PGD₂ sleep factor 17
efferents to arousal systems 8, 9
GABA synthesis 4, 5
GABAergic projections to arousal systems 8, 9
glutamic acid decarboxylase (GAD) co-localization 4, 5
hypnogenic sleep factors 15–17
in the MnPN 3–4, 5, 6
in the VLPO 3–4, 5, 6
localization within the POA 3–4, 6
- neurochemical regulatory mechanisms 15–17
- phenotype 4, 5
sleep–wake switch model 14
studies of neuronal activity 6–8
see also sleep-active neurons
- prostaglandin D (PGD)
receptors 370–2
CRTH2 (DP₂) receptor 371
DP (DP₁) receptor (DPR) 371–2
location of DPR receptors 371–2
role of adenosine 372–4
- prostaglandin D synthase (L-PGDS/ β -trace) 364, 366–70
 β -trace biomarker 368–9
genetic studies 369–70
localization 368–9
structure and function 364, 366–8
- prostaglandin D₂ (PGD₂) and sleep 364–72
involvement in African sleeping sickness 366
involvement in mastocytosis 366
PGD synthase genetic studies 369–70
PGD synthase localization 368–9
PGD synthase structure and function 364, 366–8
role of adenosine 372–4
sleep factor 17

478 Index

- prostaglandin D₂ (*cont.*)
 sleep-inducing activity
 of PGD₂ 364–6
 TMN wake center 374–6
 VLPO sleep center
 374–6
- prostaglandin E₂ (PGE₂) and
 wakefulness 364,
 376–7
- prostaglandins (PG)
 discovery of 364
 range of organisms
 which have PGs
 366
 structure and formation
 364
- prostanoids, structure and
 formation 364
- ramelteon (Rozerem™)
 (melatonin agonist)
 300–1, 435
- reboxetine 437–8
- reciprocal interaction model
 of REM sleep 34–6,
 68–9
 GABAergic inhibition of
 monoaminergic
 neurons 91–4
 integration of orexins
 (hypocretins)
 389–91
 REM sleep (paradoxical
 sleep) onset and
 maintenance 86–8
- recovery sleep, cause of
 346–7
- REM muscle atonia, role of
 glycine 43
- REM-ON and REM-OFF
 neurons 34–6, 63
- REM sleep (paradoxical sleep)
 ACh release in the
 pontine reticular
 formation 110, 113,
 119–21, 122
 and enhanced EEG
 activity 109–11
 brain electrical activity
 60–1
 brain regions
 controlling 24–6
 causes of variation 61
 discovery in humans
 25–6
 discovery of 60
 effects in orexin- and
 orexin
 receptor-deficient
 rodents 415–16
 effects of ACh esterase
 inhibitors 112–16
 effects of ACh
 transporter
 blockade 110, 130,
 131
 effects of autoreceptor
 modulation of ACh
 110, 113, 121–9
 effects of blocking ACh
 degradation 109–11
 effects of choline
 transporter
 blockade 110,
 129–30
 effects of diseases 61
 effects of
 dopaminomimetics
 200
 effects of nicotine
 (cigarette smoke)
 131–2
 effects of pontine
 cholinergic agonists
 112–16
 functions 61
 in mammals and birds
 60–1
 modulation by
 urotensin II 394–5
 reciprocal interaction
 model 34–6
 role of acetylcholine
 27–8
 species which show it
 60–1
 variation with age 61
see also paradoxical sleep
 (PS)
- REM sleep behaviour
 disorder, in
 Parkinson's disease
 202, 203, 205–6
- REM sleep deprivation
 and hypothermia 71–3
 and increased food
 intake 71–3
 effects of increased NA
 levels in the brain
 71–3
 mechanisms for adverse
 effects 71–3
 patho-physiological
 effects 61
- REM sleep disorders, and
 dopamine activity
 179
- REM sleep dysregulation, in
 orexin- and orexin
 receptor-deficient
 rodents 415
- REM sleep generation
 role of muscarinic
 cholinergic
 receptors 115,
 116–18
 role of the LC 61–3
 role of the pontine
 region 61–3
 role of the pontis
 reticularis oralis
 61–3

- REM sleep regulatory
 neurotransmitters
 63–70
 acetylcholine 66
 dopamine 65
 GABA 66–8
 GABAergic Inhibition
 Based Model 69–70,
 71
 histamine 65–6
 interactions between
 68–70
 Mutual Inhibitory Model
 69
 noradrenaline 63–4
 orexin (hypocretin) 68
 Reciprocal Interaction
 Model 68–9
 serotonin 65
reptiles, brain electrical
 activity in rest state
 60–1
reserpine (from *Rauwolfia*
vomitoria) 33
restless legs syndrome 179,
185
reverse genetics, use in the
 study of
 neuropeptides
 388–9, 392, 396
risperidone 438
schizophrenia, sleep
 disturbances
 438–40
sedative hypnotic drugs,
 actions 17
selective serotonin reuptake
 inhibitors (SSRIs)
 31
 effects on 5-HT_{1A}
 receptor 259–60
serotonergic dorsal raphe
 neurons 247
 afferent connections
 249, 250
 efferent connections
 247–8, 249
 rates of firing in
 sleep–wake
 regulation 250–2
serotonergic median raphe
 neurons 247
 afferent connections
 249, 250
 efferent connection
 247–8, 249
serotonergic raphe neurons
 29–32
 activity levels 31–2
 auto- and
 heteroreceptors
 32
 caudal group 247
 control of activity and
 serotonin release
 32
 distribution 31
 rostral group 247
serotonin (5-hydroxy-
 tryptamine, 5-HT)
 and PGO spikes 32
 and REM sleep
 regulation 65
 changing view of role in
 sleep–wake
 regulation 246–7
 discovery 29
 discovery of
 neurotransmitter
 function 29
 effects on sleep 31–2
 enhancement of
 extracellular levels
 31
 monoaminergic theory
 of sleep and waking
 31–2
 range of functions
 256–7
 structure 29
 synthesis and
 catabolism 29–30,
 31
 serotonin receptors *see* 5-HT
 receptors
 serotonin reuptake
 inhibitors 435–6
 serotonin reuptake
 transporters (SERT)
 31
 sleep-active neurons
 in the basal forebrain
 (BF) 6
 in the hypothalamic
 POA 3
 see also preoptic area
 (POA) sleep-active
 neurons
 sleep-active warm-sensitive
 neurons (WSNs)
 in the POA 10–14
 inhibition of arousal
 systems 13, 14
 sleep and wakefulness
 electrophysiological
 correlates 60–1
 variations in the state of
 consciousness
 60–1
 see also sleep–wake
 regulation
 sleep deprivation
 and energy imbalance
 346–7
 cause of recovery sleep
 346–7
 cause of rise in
 adenosine 346–7
 effects of energy
 imbalance 346–7
 effects of NO 346–7

480 Index

- sleep deprivation (*cont.*)
 source of increased
 adenosine 345–6
 vulnerability of the
 prefrontal cortex
 125, 126
- sleep disorder treatments
 (serotonin-related)
 31
- sleep disorders
 adenosine applications
 352–3
 melatonin treatment
 291–4
 periodic leg movement
 179
 potential use of
 glutamate receptor
 agonists/antagonists
 239–40
 REM sleep disorders
 179
 restless legs syndrome
 179
 treatment with
 melatonin agonists
 299–301
- sleep factors
 criteria for 337–8
 cytokines 316
 definition 328–9
 early research 337–8
 ghrelin 318–21, 322,
 323
 interferon alpha 2 316
 interleukin 1 (IL-1) 316
 neuropeptide Y (NPY)
 319, 321–2, 323
 neurotransmitters and
 neuromodulators
 317–18
 nitric oxide (NO) 322–8
 obestatin 321
 orexin 318, 322, 323
- orexin-ghrelin-NPY
 circuit 318–22, 323
 scope of search for
 317–18
 tumor necrosis factor α
 (TNF α) 316
see also adenosine;
 hypnogenic sleep
 factors
- sleep factors, history of
 attempts to isolate a
 sleep factor from
 animals 315–17
 delta-sleep-inducing
 peptide (DSIP)
 316–17
 historical search for the
 ‘hypnotoxin’, in
 315–17
 muramyl peptides
 (Factor S) 315–16
 search for a key
 endogenous
 substance 315–17
 search for a key
 hormone 315–16
 somnogenic action of
 cytokines 316
 SPS-A and SPS-B 317
- sleep modulation by
 melatonin (human)
 290–1
 circadian phase-shifting
 effects of melatonin
 293–4
 effects of endogenous
 melatonin
 administration
 291–4
 neuropharmacological
 mechanisms
 295–9, 300
 opening of the sleep
 gate 290–1
- treatment of age-related
 circadian changes
 294
 treatment of circadian
 rhythm problems in
 blind people 294
 treatment of delayed
 sleep phase
 syndrome 294
 treatment of jet lag
 symptoms 293–4
 treatment of sleep
 disorders 291–4
 wake-maintenance zone
 (‘forbidden zone’)
 291
- sleep-onset REM periods
 (SOREMs), in
 Parkinson’s disease
 202–5
- sleep paralysis 405, 406
- sleep propensity, and body
 temperature 10–14
- sleep regulation *see* sleep
 factors; sleep-wake
 regulation
- sleep switch (flip-flop) model
 40, 41–2
- interaction of orexin
 (hypocretin) and
 MCH 426
- proposed role of orexin
 (hypocretin)
 neurons 391
- role of neuropeptide S
 (NPS) 395–6, 397
- role of POA sleep-active
 neurons 14
- sleep-wake regulation
 Borbély’s two-process
 theory 337
 changing view of role of
 serotonin (5-HT)
 246–7

- circadian process 337
- criteria for sleep factors 337–8
- early research 337–8
- effects of glutamate neurotransmission 225–8
- homeostatic process 337, 338
- humoral theory 363
- influence of energy balance 424–7
- interaction of orexin and MCH 424–7
- neural structures involved 244–6
- neurotransmitters involved 244–6
- role of 5-HT_{1A} receptor 257–60
- role of 5-HT_{1B} receptor 260
- role of 5-HT_{2A/2B/2C} receptors 261–3
- role of 5-HT₃ receptor 263–4
- role of 5-HT₇ receptor 264–5
- role of cortistatin 392–4
- role of neuropeptide S (NPS) 395–6, 397
- role of orexins (hypocretins) 388–91
- role of the lateral hypothalamus (LH) 424–6
- role of urotensin II 394–5
- search for endogenous somnogenic substances 363
- search for sleep factors 337–8
- sleep–wake regulatory neurons, rates of firing 250–2
- sleep–wake stages, neurotransmitter systems involved 433
- slow wave sleep, effects of cortistatin 392–4
- smoking, effects on sleep 131–2
- soluflazine 340
- somatostatin 392
- somatostatin receptors 392
- state-related dysfunction, in Parkinson's disease 202–6
- stimulants, adenosine receptor targets 45
- sublaterodorsal nucleus (SLD), role in paradoxical sleep 88–91
- subparafascicular thalamus, dopamine cell group 185
- suprachiasmatic nucleus actions of NO 327–8 control of melatonin secretion 285–6 effects of glutamate neurotransmission 226
- synaptic plasticity, promotion of 34
- thalamocortical arousal state dysfunction, in Parkinson's disease 202–5
- thalamus acetylcholine release 27 effects of glutamate neurotransmission 227–8
- theophylline, adenosine receptor targets 45
- thermoregulation, and sleep 10–14
- TMN *see* tuberomammillary nucleus
- trazodone 437
- tricyclic antidepressants (TCAs) 435–6
- tuberohypophyseal dopamine pathway 184–5
- tuberoinfundibular dopamine pathway 184–5
- tuberomammillary nucleus (TMN), effects of PGD₂ 374–6
- tuberomammillary nucleus (TMN) histaminergic neurons 36–8, 147–8 action of histamine on 151 action of neurotransmitters and neuromodulators on 151–3 activity during wakefulness 145 activity levels 37–8 afferents to 150 dopaminergic inputs 150 efferent projections in the CNS 148–9 GABAergic inputs 150 galanin inputs 150 localization in the TMN 37

Cambridge University Press

978-0-521-86441-1 - Neurochemistry of Sleep and Wakefulness

Edited by Jaime M. Monti, S. R. Pandi-Perumal and Christopher M. Sinton

Index

[More information](#)

482 Index

- tuberomammillary nucleus (TMN) (*cont.*)
 method of release of histamine 37
 orexinergic inputs 150
 physiology 150–1
- tumor necrosis factor α (TNF α), as a sleep factor 316
- urotensin II
 and sleep–wake regulation 394–5
 effect on peripheral vasculature 394–5
 modulation of REM sleep 394–5
- valproic acid 289–90
- venlafaxine 437–8
- ventrolateral POA (VLPO)
 case for A₂A-mediated action in 349, 350–2
- effects of prostaglandin D₂ (PGD₂) 374–6
- efferents to arousal systems 8
- GABAergic neurons 40–1
- sleep-active neurons 3–4, 5, 6
- vesicular ACh transporter blockade, effects on REM sleep 110, 130, 131
- vigilance states, effects of orexin deficiency 422–4
- VLPO *see* ventrolateral POA
- voltammetry 23–4
- wake-maintenance zone (“forbidden zone”) 291
- wake-promoting neuronal groups, studies of neuronal activity 8
- wake–sleep regulation *see* sleep–wake regulation
- wake–sleep transitions *see* sleep switch (flip–flop) model
- wakefulness
 activity of monoaminergic systems 145
- brain regions controlling 24–6
- cortical activation by neurotransmitters 145
- EEG activity 145
- warm-sensitive neurons (WSNs) in the POA 10–14
- zolpidem 434, 437–8
- zopiclone 434